Accordingly, a number of pharmacological Fscn1 inhibitors have been developed, which impaired tumor cell migration in vitro by inhibiting the interaction of Fscn1 with F-actin [37,38] and accordingly attenuated tumor growth in preclinical mouse models [19]. The gene discussed is FSCN1; the disease is neoplasm.